Moderna MRNA Stock Price, News & Analysis
The first mRNA mpox vaccine to be pitted against licensed vaccines beat its rivals by easing symptoms and potentially cutting transmission, according to new research published Tuesday, a coup for manu… Key Data The 13 analysts with 12-month price forecasts for Moderna stock have an average target of 127, with a low estimate of 80 […]
Daha Fazla Oku